

The University of Chicago Genetic Services Laboratories



5841 S. Maryland Ave., Rm. G701, MC 0077, Chicago, Illinois 60637
Toll Free: (888) UC GENES ☐ (888) 824 3637
Local: (773) 834 0555 ☐ FAX: (773) 702 9130
ucgslabs@genetics.uchicago.edu ☐ dnatesting.uchicago.edu
CLIA #: 14D0917593 CAP #: 18827-49

Genetic Testing for Rubinstein Taybi Syndrome

Clinical Features:

Patients with Rubinstein-Taybi syndrome (RSTS) [OMIM #180849] have characteristic facial features, short stature, broad (often angulated) thumbs and great toes, and moderate to severe mental retardation. Facial features include arched eyebrows, down-slanting palpebral fissures, a beaked nose with long columella, high arched palate, and grimacing smile. Many patients with RSTS develop obesity in childhood or adolescence. Other features include eye findings, undescended testes, urinary tract anomalies, and congenital heart defects. Patients with RSTS also have an increased risk for tumors including meningioma, pilomatrixoma, rhabdomyosarcoma, pheochromocytoma, and leukemia (1).

Molecular Genetics:

Mutations of the *CREBBP* (CREB binding protein) [OMIM #600140] gene have been identified in a majority of patients with RSTS (2). *CREBBP* encodes a co-activator in cyclic-AMP-regulated gene expression and has 31 coding exons. Approximately 10-20% of patients with RSTS have deletions involving the *CREBBP* gene. These deletions may be as small as single exon or include the entire *CREBBP* gene along with other nearby genes (1). Intragenic deletions/duplications will not be detected by FISH or genomic CGH analysis. In addition, 30-50% of patients with RSTS have mutations in the *CREBBP* gene (3, 4). Nonsense, missense, frameshift and splicing mutations have all been identified in the *CREBBP* gene (4).

Mutations of the *EP300* (E1A binding protein, 300-KD) [OMIM #602700] gene have been identified in approximately 3% of patients with RSTS (1, 5). *EP300* encodes a histone acetyltransferase that is important in the process of cell proliferation and differentiation and has 31 coding exons. Only nonsense mutations, frameshift and interstitial deletions have been identified in the *EP300* gene to date.

Mutations in either gene are associated with the classic facial features, mental retardation and other abnormalities typically associated with RSTS (5).

Inheritance:

RSTS is an autosomal dominant condition that occurs in 1 in 125,000 live births. Most cases appear to be *de novo*. Recurrence risk for unaffected parents of an isolated case is approximately 0.1%. Individuals with RSTS rarely reproduce. Recurrence risk for affected individuals is theoretically 50%.

Additional Resources:

Rubinstein-Taybi Parent Group

PO Box 146

Smith Center KS 66967

Phone: 888-447-2989; 785-697-2984

Fax: 785-697-2985

Email: lbaxter@ruraltel.net

Test methods:

We offer full gene sequencing of the entire coding region for *CREBBP* and *EP300*. We also offer deletion/duplication analysis of the *CREBBP* and *EP300* genes by MLPA or oligonucleotide array-CGH to identify deletions/duplications of one or more exons. Partial exonic copy number changes and rearrangements of less than 400 bp may not be detected by array-CGH. Array-CGH will not detect low-level mosaicism, balanced translocations, inversions, or point mutations that may be responsible for the clinical phenotype. This testing will also detect the 16p13.3 microdeletion. The sensitivity of our deletion/duplication assay may be reduced when DNA is extracted by an outside laboratory. For best results, please provide a fresh blood sample for this testing.

CREBBP sequencing analysis

Sample specifications: 3 to10 cc of blood in a purple top (EDTA) tube
Cost: \$2400
CPT codes: 81407
Turn-around time: 4 - 6 weeks

CREBBP deletion/duplication testing

Sample specifications: 3 to10 cc of blood in a purple top (EDTA) tube
Cost: \$1000
CPT codes: 81406
Turn-around time: 4 weeks

EP300 sequencing analysis

Sample specifications: 3 to10 cc of blood in a purple top (EDTA) tube
Cost: \$2400
CPT codes: 81407
Turn-around time: 4 - 6 weeks

EBP deletion/duplication testing

Sample specifications: 3 to10 cc of blood in a purple top (EDTA) tube
Cost: \$1000
CPT codes: 81406
Turn-around time: 4 weeks

Testing for a known mutation in additional family members by sequence analysis

Sample specifications: 3 to10 cc of blood in a purple top (EDTA) tube
Cost: \$390
CPT codes: 81403
Turn-around time: 3-4 weeks

Prenatal testing for a known mutation by sequence analysis

Sample specifications: 2 T25 flasks of cultured cells from amniocentesis or CVS
or 10 mL of amniotic fluid
Cost: \$540
CPT codes: 81403
Turn-around time: 1-2 weeks

Results:

Results, along with an interpretive report, will be faxed to the referring physician. Additional reports will be provided as requested. All abnormal results will be reported by telephone.

References:

1. Stevens C. Rubinstein-Taybi Syndrome. In: Pagon R, Bird T, Dolan C, eds. GeneReviews [Internet]. Seattle: University of Washington, 2002.
2. Petrij F, Giles RH, Dauwerse HG et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 1995; 376: 348-351.
3. Bartsch O, Schmidt S, Richter M et al. DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein-Taybi syndrome (RSTS) and in another patient with incomplete RSTS. Hum Genet 2005; 117: 485-493.
4. Roelfsema JH, White SJ, Ariyürek Y et al. Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. Am J Hum Genet 2005; 76: 572-580.
5. Bartholdi D, Roelfsema JH, Papadia F et al. Genetic heterogeneity in Rubinstein-Taybi syndrome: delineation of the phenotype of the first patients carrying mutations in EP300. J Med Genet 2007; 44: 327-333.

Committed to CUSTOMIZED DIAGNOSTICS, TRANSLATIONAL RESEARCH & YOUR PATIENTS' NEEDS